SU2C Multiple Myeloma Dream Team: Screening and Interception of Precursor Myeloma


Irene Ghobrial, MD

Irene Ghobrial, MD
Associate professor of medicine, Dana-Farber Cancer Institute


Ivan M. Borrello, MD

Ivan M. Borrello, MD
Director, Cell Therapy and GMP Biologics Core, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


Multiple Myeloma (MM) is an incurable cancer of the plasma cells. Almost all patients diagnosed with MM have had one of two precursor conditions called monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) before their disease has caused damage to organs such as bone lesions, fractures and kidney failure. However, most patients are not diagnosed with these precursor conditions because there is no routine screening for them.

MGUS is a very common condition that affects 3 percent of the general population aged 50 years or older and increases with age. It is 3 times more common in African-Americans and presents at an even younger age in this population. Unlike expensive and controversial screening studies for other cancers, MGUS can be screened for by a simple blood test. However, this has not been the practice to date.

The SU2C Multiple Myeloma Dream Team revolves around a simple idea: to screen individuals who are at high risk of developing MGUS/SMM. By identifying them early, the Team can possibly develop therapies that prevent myeloma, making myeloma a cancer that can be prevented by early screening and interception.

The hypothesis of this proposal is that early detection of MGUS/SMM in a high-risk population, along with a good understanding of the molecular and immune factors that lead to disease progression, will lead to effective strategies that intercept disease progression and improve survival.

The Dream Team proposes to conduct a screening study of individuals over the age of 45, who are at a high risk for having MGUS or SMM, such as African-Americans and individuals who have a first-degree relative that has been diagnosed with a plasma cell disorder. This study will be called the PROMISE study.  We will focus on these populations because they are two to three-fold more likely than others to have these precursor conditions.

The Team expects to screen 50,000 individuals to obtain 3,000 MGUS/SMM cases to intensively study and follow over time as a cohort. The Dream Team will study this cohort in an effort to define biological characteristics that will help to identify which patients will benefit from particular therapies. These biological characteristics include inherited mutations, acquired mutations, and immune factors. The Dream Team will also identify lifestyle and demographic factors that contribute to disease progression, such as obesity and race.

The Dream Team will use this information to develop new therapeutics that can be used to prevent MM from progressing. These include novel technologies of nanoparticles for better imaging of early disease and the first personalized neoantigen vaccine study for the population of patients screened.

Together, these studies promise to change the landscape of myeloma diagnosis/screening and early prevention and interception of this disease. These studies will not only lead to better molecular markers that predict progression but also define therapeutic options that will make MM a preventable or possibly curable disease.

Amount Of Funding:

$10 million



Joseph R. Mikhael, MD, professor of medicine, Mayo Clinic Arizona

Jeremiah A. Johnson, PhD, assistant professor, Massachusetts Institute of Technology

Gad Getz, PhD, Broad Institute

Lorelei Ann Mucci, MPH, ScD, associate professor of epidemiology, Harvard T.H. Chan School of Public Health


Timothy Rebbeck, PhD, professor of epidemiology, DFCI


Viktor A. Adalsteinsson, PhD, research scientist, Broad Institute


Cheryl Boyce, executive director emeritus, Ohio Commission on Minority Health

Jenny Ahlstrom, president and founder, Myeloma Crowd - Crowd Care Foundation